Gene · 1974
EIF4A2: eukaryotic translation initiation factor 4A2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EIF4A2: eukaryotic translation initiation factor 4A2. Genes, record 1974. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1974
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14240 | Eukaryotic initiation factor 4A-II | 407 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 45548 | Q14240 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5661 | Q14240 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5314 | Q14240 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5314 | Q14240 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5661 | Q14240 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 28852 | Q14240 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 131823 | Q14240 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 3473 | Q14240 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 225983 | Q14240 | Espacenet |
| EP 3394291 A1 | 2018-10-31 | 221 | Q14240 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,193
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EIF4A2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 24 | 2025 |
| P01CA125066 | Discovery of Anticancer Agents of Diverse Natural Origin | 15 | 2025 |
| R35GM118173 | Chemical Synthesis of Complex Natural Products for Translational Science | 15 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 11 | 2025 |
| ZIAHD001004 | Molecular Mechanisms of Translational Control | 10 | 2025 |
| R35GM122602 | Mechanisms of eukaryotic translation and ribosome-associated mRNA surveillance and protein quality control | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 7 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 7 | 2025 |
| R01GM056927 | Control of Translation in Herpesvirus Infected Cells - Resubmission - 1 | 7 | 2025 |
1 to 10 of 2,193Source NIH's project files
See all 2,193 nih grantsPapers3,023
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Dimeric Protein-RNA Glue Promotes Multivalent eIF4A-RNA Assembly. | ACS Cent Sci | 2026 | 42666664 | PubTator, text mining | PubMed |
| Poly(A)-binding proteins in trypanosomatids and Plasmodium. | J Biosci | 2026 | 42615421 | PubTator, text mining | PubMed |
| Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy. | EMBO Mol Med | 2026 | 42477455 | PubTator, text mining | PubMed |
| Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma. | Sci Adv | 2026 | 42467756 | PubTator, text mining | PubMed |
| Molecular Feasibility of Gene Sequencing on Lymph Node Fine-Needle Cytology Samples of Non-Hodgkin Lymphoma. | Int J Mol Sci | 2026 | 42450228 | PubTator, text mining | PubMed |
| 40S ribosomal subunits move along the 5' UTR through an eIF4A-independent mechanism in higher eukaryotes. | bioRxiv | 2026 | 42395458 | PubTator, text mining | PubMed |
| Remodeling of mRNA by eIF4F in human translation initiation. | bioRxiv | 2026 | 42367976 | PubTator, text mining | PubMed |
| Structural insights into the recruitment of viral type 2 IRES to ribosomal preinitiation complex for protein synthesis. | Elife | 2026 | 42345371 | PubTator, text mining | PubMed |
| Extracellular vesicle cargo dynamics in the bone marrow microenvironment: from hematopoietic homeostasis to malignant transformation. | Extracell Vesicle | 2026 | 42344609 | PubTator, text mining | PubMed |
| Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. | Cell Rep | 2026 | 42284146 | PubTator, text mining | PubMed |
1 to 10 of 3,023
See all 3,023 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1974
GET https://conductscience.org/api/genes/v1/1974/patents?page=2